Correction
Medicine, General & Internal
Karim Fizazi, Neal Shore, Teuvo L. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R. Smith
Summary: This article points out incorrect data regarding the application of Darolutamide in nonmetastatic, castration-resistant prostate cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Health Care Sciences & Services
Fernando Lopez-Campos, Antonio Conde-Moreno, Marta Barrado Los Arcos, Antonio Gomez-Caamano, Raquel Garcia-Gomez, Asuncion Hervas Moron
Summary: The combination of ADT with apalutamide, enzalutamide, and darolutamide has shown significant clinical benefits for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC), including improved overall survival (OS). Therefore, these approaches are now considered standard of care and included in treatment guidelines for nmCRPC patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Medicine, General & Internal
Kelli M. Rasmussen, Vikas Patil, Chunyang Li, Christina Yong, Sreevalsa Appukkutan, Jamie Partridge Grossman, Jay Jhaveri, Ahmad S. Halwani
Summary: This study examines clinical outcomes by race and ethnicity in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) within the US Veterans Health Administration. The results suggest that there are differences in outcomes by race and ethnicity, and Black and Hispanic men may have considerably improved outcomes when treated in an equal-access setting.
Review
Oncology
Carlo Cattrini, Orazio Caffo, Ugo De Giorgi, Alessia Mennitto, Alessandra Gennari, David Olmos, Elena Castro
Summary: This review discusses the use of apalutamide, darolutamide, and enzalutamide in patients with nmCRPC and the clinical implications of novel imaging techniques for treatment selection.
Article
Urology & Nephrology
Susan Halabi, Shan Jiang, Emi Terasawa, Viviana Garcia-Horton, Rajeev Ayyagari, A. Reginald Waldeck, Neal Shore
Summary: This study compared the safety and efficacy of darolutamide vs apalutamide, and darolutamide vs enzalutamide in nonmetastatic castration-resistant prostate cancer through matching-adjusted indirect comparisons. While there were no differences in metastasis-free survival, darolutamide showed lower rates of certain adverse events compared to apalutamide and enzalutamide, suggesting a more favorable safety and tolerability profile.
JOURNAL OF UROLOGY
(2021)
Article
Multidisciplinary Sciences
Yuji Hakozaki, Yuta Yamada, Taketo Kawai, Masaki Nakamura, Yuta Takeshima, Takuya Iwaki, Taro Teshima, Yoshitaka Kinoshita, Yoichi Fujii, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Motofumi Suzuki, Mayu Kashiwagi-Hakozaki, Tetsuo Ushiku, Haruki Kume
Summary: This study aimed to identify prognostic factors for cancer-specific survival in non-metastatic castration-resistant prostate cancer patients. The analysis of 82 patients revealed that PSA doubling time and time to CRPC diagnosis were significant predictors of CSS, leading to the development of a novel risk stratification.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Andrei Sergeyev, Lin Gu, Amanda M. De Hoedt, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Zachary Klaassen, Martha K. Terris, Lourdes Guerrios-Rivera, Stephen J. Freedland, Ilona Csizmadi
Summary: The study found that diabetes identified by ICD-9/10 codes was associated with better overall survival in late-stage prostate cancer patients, while the "undiagnosed" diabetes identified by high HbA1c values was associated with an increase in all-cause mortality. In addition, the duration of diabetes prior to diagnosis was inversely associated with prostate cancer-specific mortality.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Article
Oncology
Felix Y. Feng, Shibu Thomas, Fred Saad, Michael Gormley, Margaret K. Yu, Deborah S. Ricci, Brendan Rooney, Sabine Brookman-May, Sharon McCarthy, David Olmos, Simon Chowdhury, Boris Hadaschik, Yang Liu, Elai Davicioni, Matthew R. Smith, Eric J. Small
Summary: The GC score and basal-luminal subtype derived from archived tumor specimens could be potential biomarkers for predicting response to apalutamide+ADT in nmCRPC patients. Although the addition of apalutamide to ADT was beneficial overall, higher-risk and luminal subtypes appeared to benefit most.
Review
Oncology
Fred Saad, Martin Boegemann, Kazuhiro Suzuki, Neal Shore
Summary: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is characterized by rising PSA levels despite castration therapy, and patients are at risk of developing metastatic disease and cancer-related symptoms. Treatment decisions for nmCRPC patients should consider the balance between clinical benefits and potential adverse events of second-generation androgen receptor inhibitors to delay metastases and prolong survival.
PROSTATE CANCER AND PROSTATIC DISEASES
(2021)
Review
Oncology
Neal Shore, Viviana Garcia-Horton, Emi Terasawa, Rajeev Ayyagari, Jamie Partridge Grossman, Adrianus Reginald Waldeck
Summary: Prostate cancer is a common cancer in men and initial treatments focus on reducing male hormones to control the cancer. However, some patients stop responding to these treatments and need more advanced options. Three novel therapies have become available for nonmetastatic castration-resistant prostate cancer, raising the question of how to choose the right treatment. Patient safety is crucial in treatment selection, considering the differences in safety profiles and potential harm. The selection should also consider patient preferences, clinical characteristics, and potential healthcare complications.
Review
Pharmacology & Pharmacy
Arnaldo Figueiredo, Luis Costa, Maria Joaquina Mauricio, Luis Figueira, Rodrigo Ramos, Carlos Martins-da-Silva
Summary: Prostate carcinoma is a highly prevalent and diverse disease. Nonmetastatic castration-resistant prostate cancer is a transient stage that most patients eventually progress to metastatic lesions. Treatment decisions for this population are challenging due to disease heterogeneity.
CLINICAL DRUG INVESTIGATION
(2022)
Article
Oncology
Joan Carles, Rafael A. Medina-Lopez, Javier Puente, Alvaro Gomez-Ferrer, Javier Casas Nebra, Maria Isabel Saez Medina, Maria J. Ribal, Alfredo Rodriguez Antolin, Jose Luis Alvarez-Ossorio, Jose Francisco Suarez Novo, Cristina Moretones Agut, Shankar Srinivasan, Jorge Ortiz, Karim Fizazi
Summary: In the Phase III ARAMIS study, darolutamide significantly prolonged metastasis-free survival in patients with high-risk nonmetastatic castration-resistant prostate cancer. In this post hoc analysis, Spanish participants treated with darolutamide had a longer metastasis-free survival compared to those treated with placebo, with similar treatment-emergent adverse events.
Review
Oncology
Mathieu Roumiguie, Xavier Paoletti, Yann Neuzillet, Romain Mathieu, Sebastien Vincendeau, Francois Kleinclauss, Arnaud Mejean, Laurent Guy, Marc Olivier Timsit, Thierry Lebret
Summary: The study compared the efficacy, safety, and health-related quality of life of apalutamide, enzalutamide, and darolutamide in patients with nonmetastatic castration-resistant prostate cancer. Results showed that all three drugs significantly prolonged survival compared to placebo and were generally well tolerated. Therefore, drug selection in clinical practice should be based on individual patient factors such as tolerability, drug interactions, and comorbidities.
Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
